Source comparison
Best ARA-290 Dosage for Diabetes Complications: Comparison
4mg three times weekly Subcutaneous injection (Monday/Wednesday/Friday) Phase 2 RCT (ACTION trial, Diabetes Care 2015) 42% reduction in neuropathic pain; 1.8 fibers/mm² increase in corneal nerve density at 12 weeks Injection site reactions in 8%; no hematologi
This comparison does not assign a generated winner or score.
- 4mg three times weekly
- Subcutaneous injection (Monday/Wednesday/Friday)
- Phase 2 RCT (ACTION trial, Diabetes Care 2015)
- 42% reduction in neuropathic pain; 1.8 fibers/mm² increase in corneal nerve density at 12 weeks
- Injection site reactions in 8%; no hematologic effects
- Standard protocol with strongest clinical evidence for diabetic neuropathy. Therapeutic ceiling effect observed, making higher doses unnecessary
- 8mg daily for 14 days
- Subcutaneous injection
- Phase 1 dose-escalation study
- No additional benefit over 4mg three-times-weekly regimen
- Similar safety profile to 4mg but no efficacy gain
- Not recommended. Receptor saturation likely; more frequent dosing without proportional benefit
- 1–2mg intermittent
- Preliminary trials
- Inconsistent pain reduction; no measurable change in nerve fiber density
- Minimal adverse events
- Below therapeutic threshold. Insufficient IRR activation for sustained neuroprotection
- Off-label higher dosing
- Variable
- No published data
- Unknown
- Unknown risk profile at doses above 8mg
- Not supported by evidence. No known mechanism for additional benefit and potential unknown risks